Aurobindo Pharma launches TheraNym as MSD anchor deal strengthens biologics CDMO push
Find out how Aurobindo Pharma’s TheraNym launch could reshape India’s biologics CDMO ambitions and investor sentiment.
Can LIFT and NorthStar move Lu-177-LT17 into the next radioligand therapy frontier?
Find out how LIFT and NorthStar’s Lu-177-LT17 partnership could advance radioligand therapy for cancer bone disease today!
Can Curia’s Valladolid upgrade raise the bar for sterile API manufacturing?
Find out how Curia’s $4m Valladolid aseptic suite upgrade could strengthen sterile API manufacturing and Annex 1 readiness.
Can Oxford Nanopore and Lonza fix the mRNA quality control bottleneck?
Find out how Oxford Nanopore and Lonza’s GMP mRNA QC solution could simplify release testing for next-generation RNA medicines.
Can payload-linker manufacturing help Piramal Pharma Solutions reset CDMO momentum?
ADC demand is rising, but manufacturing remains a bottleneck. Piramal Pharma Solutions is betting Riverview can narrow that gap.
Can Siegfried turn Noramco’s controlled-substance expertise into a global CDMO edge?
API security is becoming a CDMO battleground. Siegfried’s Noramco deal tests whether complex small molecules can drive the next growth phase.
Tivic Health Systems becomes Valion Bio but the real story lies in its biodefense pivot
Valion Bio’s pivot to biodefense and oncology could reshape biotech funding. Find out what this transformation means for investors and the industry.
Scinai Immunotherapeutics doubles CDMO revenue, but can the Recipharm deal change the bigger picture?
Scinai Immunotherapeutics doubled CDMO revenue in 2025. Read what the Recipharm deal and PC111 focus could mean for its biotech strategy.
How Piramal Pharma Solutions’ Morpeth tablet press upgrade sharpens its play in potent oral solid manufacturing
Piramal Pharma Solutions has added new high-containment tablet capacity at Morpeth. Read what this could change for CDMO competition and potent drug supply.
LGM Pharma’s $15m U.S. manufacturing expansion signals a deeper shift away from import dependence in pharma supply chains
LGM Pharma expands U.S. CDMO capacity with a $15M investment across Texas and Colorado. Explore what this means for domestic drug manufacturing. Read more.